As inflammation and cytokine (including chemokine) release can occur via similar receptor pathways in pulmonary injury and SARS-CoV-2, we reviewed the literature surrounding the CCR5 and CCR2 pathways and the rationale for CVC as a potential agent in the treatment of patients with COVID-19 [26,30]. This evidence concerns the gene CCR5 and COVID-19.